How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?

Y I Sheline1, K E Freedland, R M Carney

  • 1Washington University School of Medicine, St Louis, Missouri 63110, USA.

Insights

Selective serotonin reuptake inhibitors (SSRIs) have cardiac effects that are less understood than tricyclic antidepressants (TCAs) in patients with coronary heart disease (CHD). This review summarizes SSRI cardiac effects, interactions, side effects, and elderly efficacy, considering risk-benefit.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Depression is common in coronary heart disease (CHD) patients, increasing mortality risk.
  • Tricyclic antidepressants (TCAs) cardiac effects are known, but selective serotonin reuptake inhibitors (SSRIs) cardiac effects require further investigation.
  • Understanding SSRI cardiac profiles is crucial for managing comorbid depression and CHD.

Purpose of the Study:

  • To summarize the cardiac effects of SSRIs in patients with CHD.
  • To review potential drug interactions and side effects associated with SSRIs.
  • To evaluate SSRI efficacy in elderly patients with CHD and depression.

Main Methods:

  • Literature search of the Medline database (1986-1996) for SSRI cardiac effects.
  • Review of published reports on SSRI safety and efficacy.
  • Analysis of drug interactions and side effect profiles.

Main Results:

  • Cardiac effects of SSRIs are less characterized than TCAs.
  • SSRIs present potential drug interactions and side effects.
  • Efficacy data in the elderly with CHD is limited.

Conclusions:

  • Further research is needed to fully elucidate SSRI cardiac effects in CHD patients.
  • Careful consideration of risk-benefit is essential when prescribing SSRIs.
  • Management strategies should address both cardiac and depressive symptoms.

Related Concept Videos

G Protein-coupled Receptors01:27

G Protein-coupled Receptors

G-protein-coupled receptors are ligand-binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that traverses the cell membrane seven times, creating intracellular and extracellular loops. The extracellular loops create a ligand-specific pocket which binds to neurotransmitters or hormones. The intracellular loops hold onto the G-protein.The G-protein, or guanine nucleotide-binding protein, is a large heterotrimeric complex. Its three subunits...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...